What We Do

Icentia is a combined medical devices and service company based in Canada. It aims at providing a line of innovative medical testing solutions for healthcare institutions. Thanks to a strong understanding of the institutional healthcare environment along with important partnerships with medical specialists, Icentia is able to offer valuable solutions for major problems in the fields of medical testing.

Our mission is to help healthcare institutions become more efficient by providing unique solutions easing the process of medical testing.

Icentia has put together a seasoned management team with solid expertise in medical device development, global supply chain management, and operations in a regulated environment.

Icentia benefits from a collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) for the testing of its products. IUCPQ is one of the largest center for cardiology and pulmonology in eastern Canada.

Our Corporate Values

What Drives our Decisions

These values define us as a company not only for our clients and partners, but also for patients who benefit from our technologies. Our values describe who we are and how we do things.

We created our core values together, with guidance from who we are. These 5 elements, in which we strongly believe, carry through our thoughts in our decisions every day. Our values inspire constant innovation and drive our commitment to excellence in all we do.
— Pierre Paquet, Chief Executive Officer

Board of Directors


Richard Bordeleau has helped several innovative companies grow in international markets. After having worked as a consultant with a number of innovative companies, he held executive positions at Laboratoires Aeterna from 1994 to 1999 where he signed several partnerships with large pharmaceutical companies and played a key role in project financing. He was then president at Atrium Innovations, launching specialty chemicals and nutritional products on an international scale between 2000 and 2007.

In September 2007, he became a shareholder and director of BioCad Medical. Since the sale of BioCad to Nobel Biocare in 2009, he has been an angel investor for startups working in different sectors. He is also president of Fonds InnovExport, a $30 million fund dedicated to financing businesses developing innovative products for international markets.

Richard Bordeleau has a bachelor’s degree in business administration from the Université Laval.


Pierre brings to the company 25 years of product development and management experience with 15 years in the healthcare industry. Prior to launching Icentia, Pierre was Director of Product Management for the Innovation Center at CareFusion, a San Diego based global corporation serving the healthcare industry. Previously, he was Director of Implantable Devices in the field of active neurological implants at Victhom Human Bionics.

Pierre holds a B.S. in mechanical engineering from Laval University and a M.B.A. in management of technology from the Swiss Federal Institute of Technology in Lausanne, Switzerland.


Yannick is a seasoned executive and entrepreneur with extensive experience in high-tech product design and manufacturing. During a 5-year posting in Tokyo, Japan, Yannick managed the Telecom and Smart Card Business Unit of TÜV SÜD, one of the world's largest product certification agencies. Since then, he has been active in the management of new tech-ventures, bringing in a wealth of experience in technology, supply chain management, and contract negotiation at an international level.

Yannick graduated with a B.S. degree in electrical engineering from Laval University.


A graduate of the medical school of the Université Laval, Dr. Champagne obtained a specialty in emergency medicine at the University of Southern California in Los Angeles. He then had an active practice in emergency medicine for 10 years in Los Angeles, Quebec City, and Miami. He participated as medical director in numerous clinical research projects in oncology, dermatology, and endocrinology with different organizations in Quebec, Montreal, and Boston.

Dr. Champagne has a number of phase I to phase III clinical trials to his credit as director of clinical research. He has also been a speaker at numerous national and international scientific conferences.